COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26 center dot 2%) had myeloid, 121 (51 center dot 1%) lymphoid and 54 (22 center dot 8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3 center dot 42; 95% confidence interval (CI), 1 center dot 04-11 center dot 21; P = 0 center dot 04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0 center dot 35; 95% CI: 0 center dot 11-1 center dot 13; P = 0 center dot 08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.

Passamonti, F., Romano, A., Salvini, M., Merli, F., Porta, M., Bruna, R., et al. (2021). COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. BRITISH JOURNAL OF HAEMATOLOGY, 195(3), 371-377-377 [10.1111/bjh.17704].

COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

Romano I.;Venditti A.;Cattaneo C.;Marchetti M.;
2021

Abstract

COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26 center dot 2%) had myeloid, 121 (51 center dot 1%) lymphoid and 54 (22 center dot 8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3 center dot 42; 95% confidence interval (CI), 1 center dot 04-11 center dot 21; P = 0 center dot 04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0 center dot 35; 95% CI: 0 center dot 11-1 center dot 13; P = 0 center dot 08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15
English
Covid-19
SARS-CoV-2
leukemia
lymphoma
myeloma
Passamonti, F., Romano, A., Salvini, M., Merli, F., Porta, M., Bruna, R., et al. (2021). COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. BRITISH JOURNAL OF HAEMATOLOGY, 195(3), 371-377-377 [10.1111/bjh.17704].
Passamonti, F; Romano, A; Salvini, M; Merli, F; Porta, Mgd; Bruna, R; Coviello, E; Romano, I; Cairoli, R; Lemoli, R; Farina, F; Venditti, A; Busca, A; Ladetto, M; Massaia, M; Pinto, A; Arcaini, L; Tafuri, A; Marchesi, F; Fracchiolla, N; Bocchia, M; Armiento, D; Candoni, A; Krampera, M; Luppi, M; Cardinali, V; Galimberti, S; Cattaneo, C; La Barbera, Eo; Mina, R; Lanza, F; Visani, G; Musto, P; Petrucci, L; Zaja, F; Grossi, Pa; Bertu, L; Pagano, L; Corradini, P; Derenzini, E; Marchetti, M; Scattolin, Am; Corso, A; Tosi, P; Gherlinzoni, F; Passerini, Cg; Cavo, M; Fava, C; Turrini, M; Visco, C; Zappasodi, P; Merli, M; Mora, B; Vannucchi, Am
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/281274
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 32
social impact